Condition category
Cancer
Date applied
09/04/2009
Date assigned
17/06/2009
Last edited
10/04/2015
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Contact information

Type

Scientific

Primary contact

Prof Lindsay Turnbull

ORCID ID

Contact details

Centre for MR Investigations
Hull Royal Infirmary
Anlaby Road
Hull
HU3 2JZ
United Kingdom

Additional identifiers

EudraCT number

ClinicalTrials.gov number

NCT00978770

Protocol/serial number

Version 1

Study information

Scientific title

Establishing the efficacy of advanced semi-automated functional magnetic resonance (MR) imaging in the early prediction of response of locally advanced breast cancer to neoadjuvant chemotherapy: a pilot study

Acronym

Neo-COMICE

Study hypothesis

This proposal aims to evaluate quantitative functional magnetic resonance imaging (MRI) as an early in-vivo surrogate biomarker. Chemotherapy either directly or indirectly results in a reduction in tumour vascularity and as a consequence quantitative analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) should be predictive of response to neoadjuvant chemotherapy (NAC) and should not be treatment specific. It is essential that functional MR is compared with other markers of treatment response, namely molecular diagnostic pathology, to enable integration and potential identification of additional prognostic and predictive indicators, and this comparison will be included in a full trial that would follow this feasibility study.

It is anticipated that a subsequent multicentre trial will require around 1300 patients using standardised scan protocols and analytical techniques to provide the statistical robustness that will allow the demonstration of statistical significant changes. In preparation for such a multicentre approach, this feasibility study will use multi-parameter, easily deliverable, protocols applicable to all MR manufacturers; to ensure system stability using phantoms; evaluate the logistics of data transfer and compatibility with study software (MATLAB platform); and analyse data off-line using semi-automated segmentation techniques including Otsu's algorithm, iterative thresholding processes, edge detection and active contouring in order to extract tumour volume, and functional and textural parameters.

Quality assurance of tumour volume determination will be performed using manual contouring as the gold standard. Use of semi-automated techniques for large volume MR data analysis have already been implemented to good effect using Otsu's algorithm and other iterative techniques for delineating bone trabeculations, obtaining grey-white matter segmentation and breast lesion classification. The applicability of these techniques to breast tumour analysis by MR has been reported and critically reviewed.

The main study will require some 1300 patients, recruited from at least 60 centres, using different MRI systems, with the data being analysed centrally using semi-automated techniques. Prior to commencing the main study, the Neo-COMICE pilot study needs to be completed to test the technical feasibility of the main study, i.e. can we reliably, in a multicentre setting using different types of MRI systems, complete MRI scans to protocol, and analyse these centrally using semi-automated techniques?

This pilot study will prospectively recruit 50 patients from different centres, using the most commonly available MR systems for data acquisition, and analyse this data using centralised semi-automated techniques. This will test the technical achievability of producing multi-parameter, multi-MR system standardised protocols, ensuring the compatibility of DICOM (Digital Imaging and Communications in Medicine) information between MR manufacturers and the use of semi-automated tumour segmentation and analysis tools for data extraction. These quality-assured findings will be used to further develop the MR imaging protocol and inform the subsequent full trial application.

Ethics approval

Northern and Yorkshire Research Ethics Committee on 02/02/2009 (ref: 08/H0903/73)

Study design

Phase II multicentre prospective longitudinal observational cohort study

Primary study design

Observational

Secondary study design

Cohort study

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Breast cancer

Intervention

The trial is anticipated to have an active recruitment period of 14 months. Patients will receive MRI scans at baseline (pre-commencement of chemotherapy), 4 - 7 days after commencement of their first cycle of chemotherapy, at the end of their second cycle of chemotherapy, and at the end of their fourth cycle of chemotherapy.The only follow up data that will be routinely collected is the patients' final pathology report if the patient subsequently undergoes surgery.

Intervention type

Other

Phase

Phase II

Drug names

Primary outcome measures

1. The technical feasibility of using MR imaging in a multicentre setting using the most commonly available MR systems (i.e. is the trial able to scan patients to a specific protocol, using different types of MRI machine)
2. How reliably the imaging data can be analysed in a centralised, semi-automated, manner (i.e. can MRI data be reliably transferred from different centres and analysed using software based in the Centre for MR Investigations at the University of Hull)

Secondary outcome measures

No secondary outcome measures

Overall trial start date

01/06/2009

Overall trial end date

01/11/2010

Reason abandoned

Eligibility

Participant inclusion criteria

1. Provide written informed consent
2. Female
3. Aged 18 years or over
4. Newly diagnosed, histologically proven breast cancer (TNM stage T2- T4B, N0-3C, and M0)
5. Undergone both x-ray mammography and breast ultrasound scanning during the current treatment episode
6. Scheduled for neo-adjuvant chemotherapy

Participant type

Patient

Age group

Adult

Gender

Female

Target number of participants

50

Participant exclusion criteria

1. Are medically unstable
2. Previously undergone chemotherapy
3. Have had surgery or radiotherapy for cancer in the ipsilateral breast
4. Have had surgery to the ipsilateral breast within the previous 4 months for benign breast disease
5. Have a history of serious breast trauma within the last 3 months
6. Are pregnant or breast feeding
7. Have renal failure
8. Fail the normal safety requirements of MR, particularly pacemakers and cardiac defibrillators
9. Are known to have had an allergic reaction associated with previous administration of a paramagnetic contrast agent
10. Have a known contraindication to MR scanning
11. Have a disability preventing MR scanning in the prone position
12. Have body habitus incompatible with MR system entry

Recruitment start date

01/06/2009

Recruitment end date

01/11/2010

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Hull Royal Infirmary
Hull
HU3 2JZ
United Kingdom

Sponsor information

Organisation

Hull and East Yorkshire NHS Trust (UK)

Sponsor details

R&D Manager
Second Floor
Daisy Building
Castle Hill Hospital
Cottingham
Hull
HU16 5JQ
United Kingdom

Sponsor type

Government

Website

http://www.hey.nhs.uk/

Funders

Funder type

Charity

Funder name

Cancer Research UK (CRUK) (UK) (grant ref: C11421/A9398)

Alternative name(s)

CRUK

Funding Body Type

private sector organisation

Funding Body Subtype

other non-profit

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes